Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C

References

• Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden of disease study 2013. Lancet. 2016;388:1081–1088. DOI:10.1016/S0140-6736(16)30579-7
   PubMed Web of Science ®Google Scholar
• Arends JE, Lieveld FI, Boeijen LL, et al. Natural history and treatment of HCV/HIV coinfection: is it time to change paradigms? J Hepatol. 2015;63(5):1254–1262.
   PubMed Web of Science ®Google Scholar
• Thein HH, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48(2):418–431.
   PubMed Web of Science ®Google Scholar
• Recommendations for Testing, Managing, and Treating Hepatitis C of the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA). Available from: http://www.hcvguidelines.org [ cited 2016 Jun 5]
   Google Scholar
• European Association for the Study of the Liver (EASL) Recommendations on Treatment of Hepatitis C 2014. Available from: http://www.easl.eu/research/our-contributions/clinical-practice-guidelines/detail/recommendations-on-treatment-of-hepatitis-c-2015 [cited 2016 Jun 5]
   Google Scholar
• Pearlman BL. Protease inhibitors for the tratment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infect Dis. 2012;12(9):717–728.
   PubMed Web of Science ®Google Scholar
• Incorporated VP. INCIVEKTM (telaprevir) film coated tablets. US prescribing information. Cambridge: Vertex Pharmaceuticals Incorporated; 2013.
   Google Scholar
• Merck & Co Inc.. VICTRELIS® (boceprevir) Capsules for oral use. U.S Prescribing Information. Whitehouse Station: cited 2013 Sep.
   Google Scholar
• González-Grande R, Jiménez-Pérez M1, González Arjona C1, et al. New approaches in the treatment of hepatitis C. World J Gastroenterol. 2016;22(4):1421–1432.
   PubMed Web of Science ®Google Scholar
• HARVONI® (ledipasvir and sofosbuvir) tablets, for oral use. US prescribing information. Foster City: Gilead Sciences, Inc.; 2016.
   Google Scholar
• Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–1898.
   PubMed Web of Science ®Google Scholar
• Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483–1493.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–1888.
   PubMed Web of Science ®Google Scholar
• Naggie S, Cooper C, Saag M, et al. Ledipasvir and Sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373(8):705–713.
   PubMed Web of Science ®Google Scholar
• Bourlière M, Bronowicki JP, De Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015;15(4):397–404.
   PubMed Web of Science ®Google Scholar
• Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149(3):649–659.
   PubMed Web of Science ®Google Scholar
• Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16(6):685–697.
   PubMed Web of Science ®Google Scholar
• Gane EJ, Hyland RH, An D, et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology. 2015;149(6):1454–1461.
   PubMed Web of Science ®Google Scholar
• Abergel A, Asselah T, Metivier S, et al. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis. 2016;16(4):459–464.
   PubMed Web of Science ®Google Scholar
• Chemistry Review. Food and Drugs Administration (FDA). Chemistry Review. NDA: 205834. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205834Orig1s000Approv.pdf
   Google Scholar
• Babusis D, Curry MP, Denning JM, et al. Translational studies to understand the mechanism of liver delivery by sofosbuvir. 15th international workshop on clinical pharmacology of HIV and hepatitis therapy. 2014 May 19-21. Washington D. C., USA: Abstract O–12.
   Google Scholar
• Clinical pharmacology and biopharmaceutics review. Food and Drugs Administration (FDA). NDA: 205834. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000ClinPharmR.pdf
   Google Scholar
• Pharmacology review. Food and Drugs Administration (FDA). NDA: 205834. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205834Orig1s000PharmR.pdf
   Google Scholar
• Link J, Bannister R, Beilke L, et al. Nonclinical profile and phase I results in healthy volunteers of the novel and potent HCV NS5A inhibitor GS-5885. 61st annual meeting of the American Association for the Study of Liver Diseases (AASLD). 2010 Oct 30; Nov 2. Boston (MA), USA: Abstract 1883.
   Google Scholar
• German P, Yang J, West S, et al. Effect of food and acid reducing agents on the relative bioavailability and pharmacokinetics of ledipasvir/sofosbuvir fixed dose combination tablet. 15th international workshop on clinical pharmacology of HIV and hepatitis therapy. 2014 May 19-21. Washington D. C., USA: Abstract P–15.
   Google Scholar
• Cornpropst M, Denning J, Clemons D, et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of GS-7977. 47th Annual Meeting of the European Association for the Study of the Liver (EASL). Barcelona, Spain; 2012 Apr 18–22; p. Abstract 1101.
   Google Scholar
• Mogalian E, Mathias A, Yang J, et al. The pharmacokinetics of ledipasvir, an HCV-specific NS5A inhibitor, in HCV-uninfected subjects with severe renal impairment. The 65th annual meeting of the American Association for the Study of Liver Diseases: the liver meeting (AASLD). Boston, USA; 2014 Nov 7-11; p. Abstract 1952.
   Google Scholar
• German P, Mathias A, Yang J, et al. Pharmacokinetics of ledipasvir, an HCV-specific NS5A inhibitor, in HCV-uninfected subjects with moderate or severe hepatic impairment. 64th annual meeting of the American Association for the Study of Liver Diseases (AASLD). Washington, DC, USA; 2013 Nov 1–5; p. Abstract 467.
   Google Scholar
• Murakami E, Tolstykh T, Bao H, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem. 2010;285(45):34337–34347.
   PubMed Web of Science ®Google Scholar
• Kirby B, Gordi T, Symonds WT, et al. Population pharmacokinetics of sofosbuvir and its major metabolite (GS- 331007) in healthy and HCV-infected adult subjects. 64th annual meeting of the American Association for the Study of Liver Diseases (AASLD). Washington, DC, USA; Nov 1–5 2013. p. Abstract 1106.
   Google Scholar
• Lawitz E, Rodriguez-Torres M, Cornpropst M, et al. The effect of hepatic impairment on the safety, pharmacokinetics, and antiviral activity of GS-7977 in hepatitis C infected subjects treated for seven days. Annual Meeting of the European Association for the Study of the Liver (EASL). Barcelona, Spain; 2012 Apr 18–22; p. Abstract 1130.
   Google Scholar
• Lawitz E, Rodriguez-Torres M, Denning J, et al. All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (NUCLEAR). J Viral Hepat. 2013;20(10):699–707.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Torres M, Lawitz E, Kowdley KV, et al. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-day, dose- ranging trial. J Hepatol. 2013;58(4):663–668.
   PubMed Web of Science ®Google Scholar
• Kirby B, Hanbin L, Kearney BP, et al. Population pharmacoki- netics analysis of ledipasvir (GS-5885) in healthy and hepatitis C virus-infected subjects. 15th international workshop on clinical pharmacology of HIV and hepatitis therapy. Washington D. C., USA; 2014 May 19-21; p. Abstract P–33.
   Google Scholar